Table 2.
Comparison of the resistance pattern of the isolates to tested antibiotics between 2019 and 2021
| N ( % of total ) | MIC values | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2019 (total n = 19) | 2021 (total n = 37) | 2019 | 2021 | |||||||||
| S | I | R | SDD | S | I | R | SDD | MIC 50 | MIC 90 | MIC 50 | MIC 90 | |
| Aminoglycosides | ||||||||||||
| AK | 8(42.3) | 1(5.2) | 10(52.5) | - | 16(43.25) | 5(13.5) | 16(43.25) | - | 64 | 64 | 32 | 64 |
| GMN | 9(47.4) | 1(5.2) | 9(47.4) | - | 22(59.5) | 1(2.7) | 14(37.8) | - | 8 | 16 | 4 | 16 |
| β-lactams | ||||||||||||
| AMP | 2(10.5) | 0(0) | 17(89.5) | - | 0(0) | 0(0) | 37(100) | - | 32 | 32 | 32 | 32 |
| SAM | 1(5.2) | 0(0) | 18(94.8) | - | 0(0) | 0(0) | 37(100) | - | 512 | 2048 | 1024 | 4096 |
| TZP | 2(10.5) | - | 17(89.5) | 0(0) | 2(5.4) | - | 34(91.9) | 1(2.7) | 128 | 128 | 128 | 128 |
| AMC | 2(10.5) | 0(0) | 17(89.5) | - | 5(13.5) | 1(2.7) | 31(83.8) | - | 32 | 32 | 32 | 32 |
| CZA | 6(31.6) | 0(0) | 13(68.4) | - | 12(32.4) | 0(0) | 25(67.6) | - | 256 | 256 | 256 | 256 |
| CAZ | 3(15.8) | 0(0) | 16(84.2) | - | 0(0) | 1(2.7) | 36(97.3) | - | 64 | 64 | 64 | 64 |
| FEP | 3(15.8) | - | 14(73.7) | 2(10.5) | 2(5.4) | - | 33(89.2) | 2(5.4) | 32 | 64 | 64 | 64 |
| CRO | 0(0) | 0(0) | 19(100) | - | 0(0) | 0(0) | 37(100) | - | 16,384 | 32,768 | 16,384 | 32,768 |
| CTX | 1(5.2) | 0(0) | 18(94.8) | - | 1(2.7) | 0(0) | 36(97.3) | - | 64 | 64 | 64 | 64 |
| SCF | 0(0) | 0(0) | 19(100) | - | 0(0) | 0(0) | 37(100) | - | 1024 | 8192 | 2048 | 8192 |
| MEM | 4(21) | 0(0) | 15(79) | - | 9(24.4) | 0(0) | 28(75.6) | - | 16 | 16 | 16 | 16 |
| ETP | 2(10.5) | 0(0) | 17(89.5) | - | 8(21.6) | 0(0) | 29(78.4) | - | 4 | 8 | 8 | 8 |
| IMP | 5(26.3) | 0(0) | 14(73.7) | - | 10(27) | 0(0) | 27(73) | - | 16 | 16 | 16 | 16 |
| Fluoroquinolones | ||||||||||||
| CIP | 1(5.2) | 2(10.5) | 16(84.2) | - | 0(0) | 1(2.7) | 36(97.3) | - | 4 | 4 | 4 | 4 |
| NOR | 5(26.4) | 1(5.2) | 13(68.4) | - | 7(19) | 3(8.1) | 27(72.9) | - | 16 | 16 | 16 | 16 |
| Macrolide | ||||||||||||
| AZM | 1(5.2) | 0(0) | 18(94.8) | - | 1(2.7) | 0(0) | 36(97.3) | - | 512 | 2048 | 1024 | 4096 |
| FOS | 15(79) | 3(15.8) | 1(5.2) | - | 28(75.6) | 3(8.1) | 6(16.2) | - | 32 | 128 | 16 | 128 |
| SXT | 2(10.5) | 0(0) | 17(89.5) | - | 4(10.8) | 0(0) | 33(89.2) | - | 320 | 320 | 320 | 320 |
| DOX | 1(5.2) | 1(5.2) | 17(89.6) | - | 6(16.2) | 3(8.1) | 28(75.6) | - | 64 | 256 | 32 | 128 |
| NTF | 2(10.5) | 4(21) | 13(68.5) | - | 5(13.5) | 7(19) | 25(67.5) | - | 256 | 512 | 256 | 512 |
MIC : Minimum inhibitory concentration, SDD: Susceptible-dose dependent (which is a breakpoint category for which the susceptibility of an isolate depends on the dosing regimen used),S: Sensitive ; I : Intermediate ; R : resistant ; CIP: Ciprofloxacin; NOR: Norfloxacin; DOX: Doxycycline; NTF: Nitrofurantoin; AMP: Ampicillin ; SAM: Ampicillin/sulbactam; TZP: Piperacillin/tazobactam, AMC: Amoxicillin/clavulanic acid ; CAZ: Ceftazidime ; FEP: Cefepime ; CRO: Ceftriaxone, CTX: Cefotaxime, SCF: Cefoperazone-sulbactam ,ETP: Ertapenem; AZM: Azithromycin ; AK: Amikacin ; GMN : gentamicin ; MEM: Meropenem ; IMP :Imipenem ; CZA : Ceftazidime-avibactam ; SXT : Trimethoprim/sulfamethoxazole